The TRUPCR® AML Panel Kit is a comprehensive multiplex diagnostic solution designed for the qualitative detection of key diagnostic and prognostic markers associated with Acute Myelogenous Leukemia (AML). The assay combines conventional PCR and real-time PCR technologies to detect fusion transcripts and gene mutations with high sensitivity.
Targeting major molecular events involved in AML—including FLT3 (ITD, D835), NPM1, c-KIT, PML-RARA, AML1-ETO, CBFB-MYH11, and BCR-ABL1—this panel supports both DNA- and RNA-based analysis, with cDNA synthesis reagents provided.
Capable of detecting down to 10 copies of RNA fusion transcripts and 1% mutant allele frequency, the TRUPCR® AML Panel Kit is a powerful tool for AML diagnosis, prognosis, and therapy monitoring. It is ideal for clinical labs seeking a fast, accurate, and cost-effective workflow, compatible with most standard real-time and conventional PCR instruments.
The TRUPCR® AML Panel Kit is a dual-technology (Real-Time and Conventional PCR) in vitro diagnostic test developed for the qualitative detection of gene fusions and mutations critical to AML pathogenesis. The panel includes reagents for both RNA (fusion transcript) and DNA (mutation) analysis, with cDNA synthesis components included for RNA-based targets.
This all-in-one system detects the most common mutations and fusions associated with AML and enables labs to evaluate both Class I and Class II genetic alterations involved in disease onset and progression.
Acute Myeloid Leukemia (AML) is a genetically and phenotypically heterogeneous group of hematological malignancies arising from clonal expansion of myeloid progenitor cells with impaired differentiation. AML accounts for 15–20% of acute leukemia in children and ~80% in adults.
Genetically, AML is driven by a variety of chromosomal translocations and gene mutations. These events are traditionally categorized using the Gilliland Two-Hit Model:
Recent genomic studies have also identified a third group involving epigenetic regulators (DNMT3a, IDH1/2, TET2, WT1), which do not neatly fall into the two-hit framework but contribute significantly to AML pathogenesis.
The TRUPCR® AML Panel Kit combines high sensitivity and comprehensive target coverage in a user-friendly format:
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.
Subscribe to our newsletter.